Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells

Gynecologic Oncology

Volumn 136, Issue 3, 2015, Pages 554-561

  Teng, Pang Ning ^a   Bateman, Nicholas W ^a   Darcy, Kathleen M ^a   Hamilton, Chad A ^a,b   Maxwell, George Larry ^a,c   Bakkenist, Christopher J ^d   Conrads, Thomas P ^a  

^a BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c INOVA FAIRFAX HOSPITAL   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

ATM; ATR; Cisplatin resistance; DNA damage repair response; Gynecologic cancer; Ionizing radiation

Indexed keywords

ATM PROTEIN; ATR PROTEIN; CARBOPLATIN; CASPASE 3; CESIUM 137; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CISPLATIN; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN P53; 2-MORPHOLIN-4-YL-6-THIANTHREN-1-YL-PYRAN-4-ONE; ANTINEOPLASTIC AGENT; ATM PROTEIN, HUMAN; ATR PROTEIN, HUMAN; ETP-46464; MORPHOLINE DERIVATIVE; OXAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRONE DERIVATIVE; QUINOLINE DERIVATIVE; TUMOR MARKER;

APOPTOSIS; ARTICLE; ATAXIA TELANGIECTASIA; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CELL ACTIVITY; CELL KILLING; CHEMORADIOTHERAPY; DNA DAMAGE; DRUG EFFICACY; ENDOMETRIUM CANCER; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IONIZING RADIATION; LD 50; MORBIDITY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION RESPONSE; UTERINE CERVIX CANCER; ANTAGONISTS AND INHIBITORS; DNA REPAIR; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; EVALUATION STUDY; GENITAL NEOPLASMS, FEMALE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ATAXIA TELANGIECTASIA MUTATED PROTEINS; BIOMARKERS, TUMOR; CELL LINE, TUMOR; CISPLATIN; DNA DAMAGE; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; MORPHOLINES; OXAZINES; PROTEIN KINASE INHIBITORS; PYRONES; QUINOLINES;

EID: 84924243325     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.12.035     Document Type: Article

References (41)

1. R.R. Barakat Principles and practice of gynecologic oncology 6th ed. 2013 Wolters Kluwer/Lippincott Williams & Wilkins Heath Philadelphia
2. R. Siegel, J. Ma, Z. Zou, and A. Jemal Cancer statistics, 2014 CA Cancer J Clin 64 2014 9 29
3. A. Ciccia, and S.J. Elledge The DNA damage response: making it safe to play with knives Mol Cell 40 2010 179 204
4. W.P. Roos, and B. Kaina DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis Cancer Lett 332 2013 237 248
5. H. Zhao, and H. Piwnica-Worms ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1 Mol Cell Biol 21 2001 4129 4139
6. Q. Liu, S. Guntuku, X.S. Cui, S. Matsuoka, D. Cortez, and K. Tamai Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint Genes Dev 14 2000 1448 1459
7. Z. Chen, Z. Xiao, W.Z. Gu, J. Xue, M.H. Bui, and P. Kovar Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics Int J Cancer 119 2006 2784 2794
8. J. Smith, L.M. Tho, N. Xu, and D.A. Gillespie The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer Adv Cancer Res 108 2010 73 112
9. S. Arora, K.M. Bisanz, L.A. Peralta, G.D. Basu, A. Choudhary, and R. Tibes RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells Gynecol Oncol 118 2010 220 227
10. A.M. Huehls, J.M. Wagner, C.J. Huntoon, and L.M. Karnitz Identification of DNA repair pathways that affect the survival of ovarian cancer cells treated with a poly(ADP-ribose) polymerase inhibitor in a novel drug combination Mol Pharmacol 82 2012 767 776
11. R. Sultana, T. Abdel-Fatah, C. Perry, P. Moseley, N. Albarakti, and V. Mohan Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells PLoS One 8 2013 e57098
12. T. Abdel-Fatah, R. Sultana, R. Abbotts, C. Hawkes, C. Seedhouse, and S. Chan Clinicopathological and functional significance of XRCC1 expression in ovarian cancer Int J Cancer 132 2013 2778 2786
13. J.M. Furgason, and M. Bahassi el Targeting DNA repair mechanisms in cancer Pharmacol Ther 137 2013 298 308
14. C.J. Huntoon, K.S. Flatten, A.E. Wahner Hendrickson, A.M. Huehls, S.L. Sutor, and S.H. Kaufmann ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status Cancer Res 73 2013 3683 3691
15. A. Peasland, L.Z. Wang, E. Rowling, S. Kyle, T. Chen, and A. Hopkins Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines Br J Cancer 105 2011 372 381
16. E.M. Yazlovitskaya, and D.L. Persons Inhibition of cisplatin-induced ATR activity and enhanced sensitivity to cisplatin Anticancer Res 23 2003 2275 2279
17. R. Prevo, E. Fokas, P.M. Reaper, P.A. Charlton, J.R. Pollard, and W.G. McKenna The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy Cancer Biol Ther 13 2012 1072 1081
18. A.M. Gamper, R. Rofougaran, S.C. Watkins, J.S. Greenberger, J.H. Beumer, and C.J. Bakkenist ATR kinase activation in G1 phase facilitates the repair of ionizing radiation-induced DNA damage Nucleic Acids Res 41 2013 10334 10344
19. J. Vavrova, L. Zarybnicka, E. Lukasova, M. Rezacova, E. Novotna, and Z. Sinkorova Inhibition of ATR kinase with the selective inhibitor VE-821 results in radiosensitization of cells of promyelocytic leukaemia (HL-60) Radiat Environ Biophys 52 2013 471 479
20. I.M. Pires, M.M. Olcina, S. Anbalagan, J.R. Pollard, P.M. Reaper, and P.A. Charlton Targeting radiation-resistant hypoxic tumour cells through ATR inhibition Br J Cancer 107 2012 291 299
21. E. Fokas, R. Prevo, J.R. Pollard, P.M. Reaper, P.A. Charlton, and B. Cornelissen Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation Cell Death Dis 3 2012 e441
22. Integrated genomic analyses of ovarian carcinoma Nature 474 2011 609 615
23. C. Kandoth, N. Schultz, A.D. Cherniack, R. Akbani, Y. Liu, and H. Shen Integrated genomic characterization of endometrial carcinoma Nature 497 2013 67 73
24. K.P. Pennington, T. Walsh, M.I. Harrell, M.K. Lee, C.C. Pennil, and M.H. Rendi Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas Clin Cancer Res 20 2014 764 775
25. A.S. Turnell, and R.J. Grand DNA viruses and the cellular DNA-damage response J Gen Virol 93 2012 2076 2097
26. N.A. Wallace, and D.A. Galloway Manipulation of cellular DNA damage repair machinery facilitates propagation of human papillomaviruses Semin Cancer Biol 26 2014 30 42
27. P.M. Reaper, M.R. Griffiths, J.M. Long, J.D. Charrier, S. Maccormick, and P.A. Charlton Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR Nat Chem Biol 7 2011 428 430
28. L.I. Toledo, M. Murga, R. Zur, R. Soria, A. Rodriguez, and S. Martinez A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations Nat Struct Mol Biol 18 2011 721 727
29. I. Hickson, Y. Zhao, C.J. Richardson, S.J. Green, N.M. Martin, and A.I. Orr Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM Cancer Res 64 2004 9152 9159
30. J.S. Skilling, R.C. Squatrito, J.P. Connor, T. Niemann, and R.E. Buller p53 gene mutation analysis and antisense-mediated growth inhibition of human ovarian carcinoma cell lines Gynecol Oncol 60 1996 72 80
31. Y. Yaginuma, and H. Westphal Analysis of the p53 gene in human uterine carcinoma cell lines Cancer Res 51 1991 6506 6509
32. J. Vavrova, L. Zarybnicka, E. Lukasova, M. Rezacova, E. Novotna, and Z. Sinkorova Inhibition of ATR kinase with the selective inhibitor VE-821 results in radiosensitization of cells of promyelocytic leukaemia (HL-60) Radiat Environ Biophys 52 2013 471 479
33. P.L. Olive, and J.P. Banath Kinetics of H2AX phosphorylation after exposure to cisplatin Cytometry B Clin Cytom 76 2009 79 90
34. A. Nowosielska, M.A. Calmann, Z. Zdraveski, J.M. Essigmann, and M.G. Marinus Spontaneous and cisplatin-induced recombination in Escherichia coli DNA Repair (Amst) 3 2004 719 728
35. A. Nowosielska, and M.G. Marinus Cisplatin induces DNA double-strand break formation in Escherichia coli dam mutants DNA Repair (Amst) 4 2005 773 781
36. A. Jazayeri, J. Falck, C. Lukas, J. Bartek, G.C. Smith, and J. Lukas ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks Nat Cell Biol 8 2006 37 45
37. S.S. Liu, K.Y. Chan, R.C. Leung, H.K. Law, T.W. Leung, and H.Y. Ngan Enhancement of the radiosensitivity of cervical cancer cells by overexpressing p73alpha Mol Cancer Ther 5 2006 1209 1215
38. N. Sangster-Guity, B.H. Conrad, N. Papadopoulos, and F. Bunz ATR mediates cisplatin resistance in a p53 genotype-specific manner Oncogene 30 2011 2526 2533
39. L. Biddlestone-Thorpe, M. Sajjad, E. Rosenberg, J.M. Beckta, N.C. Valerie, and M. Tokarz ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation Clin Cancer Res 19 2013 3189 3200
40. H.C. Reinhardt, A.S. Aslanian, J.A. Lees, and M.B. Yaffe p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage Cancer Cell 11 2007 175 189
41. J.S. Skilling, A. Sood, T. Niemann, D.J. Lager, and R.E. Buller An abundance of p53 null mutations in ovarian carcinoma Oncogene 13 1996 117 123